Trametinib, also known as GSK1120212, is a n orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK
MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in
an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual
specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the
RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.
1. Supply top quality products with a reasonable price.
2. Arrange the orders and shipping with your requests on time, According to the different countries export policy provide complete customs clearance documents.
3. Samples can be arranged for testing and Unconditional assume responds.
4. Provide a price trend, ensure the clients can know about marketing informations in time.
Packing and Shipping: